[태그:] raredisease

Key Highlights Recap of Part 1 In Part 1, Changdeok Ji shared his transition from primary care blockbusters to the rare disease space. He detailed how a tripartite alliance [Pharma – AI Diagnostics – Distributor] expanded the overall diagnostic market instead of fighting over existing market share, accelerating time-to-diagnosis for rare disease patients. PART 3.…

Key Highlights Healthcare professionals stand on the front lines of changing rare disease patients’ lives. Yet, bridging the gap between identifying a rare condition and delivering treatment is a journey too complex for physicians to navigate alone. True transformation happens when the vision of clinicians aligns with the innovation of diagnostic providers and the resources…

Key Highlights 지난 1편 이야기 (Recap) 1편에서는 지창덕 상무가 안정적인 블록버스터 영역을 떠나 희귀질환 분야로 뛰어든 계기와 함께, [제약사-진단사-유통사] 3자 협력을 통해 기존 파이를 나누는 대신 진단 시장 자체를 확대해 환자의 진단 시간을 당긴 혁신적인 비즈니스 모델 구축기를 다루었습니다. PART 3. 약 도입과 급여화, 그리고 파트너십 Q. 약을 들여오는 것과 급여를 받아내는 것, 어느 쪽이…

Diagnosing Fabry disease, and the humility that comes with knowing more In part one, Professor Junhwa Lee noted that only about 5% of genetically diagnosed conditions have an approved therapy. So what happens in the conditions that do have one? How decisive is the diagnosis then? Part two starts with a disease inside that 5%…

A conversation with Professor Junhwa Lee, Department of Pediatric Neurology, Samsung Changwon Hospital Five years ago we met over Zoom for the first time. I still remember how it went. “I watched your webinar. I’d like to use the service — how do I order it?” I explained the process. His first reply: “That won’t…